2,271 press releases in English indexed under biotech & pharma.
Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma" SEOUL, South Korea and MILAN, Oct. 7, 2026 -- LG CNS, a...
LONDON, Oct. 7, 2026 -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the...
First patient enrolled in cohort combining bexobrutideg with venetoclax
Toronto, Ontario--(October 7, 2026) - Palindrome Pharma, a new pharmaceutical company focused on biosimilar medicines, today announced its launch in Canada, with a mission to broaden access to high-quality biologic therapies and contribute to a more sustainable Canadian healthcare system.As demand for biologic medicines continues to grow, biosimilars have an important role to play in creating greater choices for Canadians. Palindrome Pharma will work with global and Canadian...
New York, New York--(October 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Unicycive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs...
SAN CARLOS, Calif., Oct. 06, 2026 -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants to purchase 400,000 shares of common stock and $500 million aggregate principal amount of 1.50% convertible senior notes due 2032 (the “notes”). The shares of common stock are being sold at a public offering price of $64.00 per share, and the pre-funded warrants are being sold at a public offering price of $63.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The shares of common stock, pre-funded warrants and notes to be sold in the offerings are being offered by Vaxcyte. Vaxcyte has granted the underwriters of the common stock and pre-funded warrant offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price per share, and has granted the underwriters of the note offering a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes at the public offering price, solely to cover over-allotments, in each case less underwriting discounts and commissions.
– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer – – VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions – TOKYO, Oct. 6, 2026 -- Astellas Pharma Inc....
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York
BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress WASHINGTON, Oct. 6, 2026 -- The National Organization for Rare Disorders (NORD®) today announced that CNBC "Squawk Box" co-anchor...
National Comprehensive Cancer Network Oncology Policy Summit featured leading voices from NCI, CDC, and more. WASHINGTON, Oct. 6, 2026 -- The National Comprehensive Cancer Network® (NCCN®) hosted a two-day summit focused on expanding access to life-saving cancer prevention...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. -...
TAMPA, FLA., Oct 7, 2026 - ComplianceQuest, a leading provider of AI-powered connected Quality, Risk and Compliance (QRC) systems, and Zolon PCS, a provider of secure, mission-focused IT services to federal agencies, today announced that the U.S. Food and Drug Administration (FDA) will modernize its enterprise quality management operations on the ComplianceQuest platform. The initiative will be delivered under the FDA Cloud Quality Management System Blanket Purchase Agreement (BPA), a five-year agreement awarded to Zolon PCS as prime contractor, with ComplianceQuest as its platform partner. Together, ComplianceQuest and Zolon PCS will help FDA implement a modern, secure, AI-enabled quality management solution built on the Salesforce FedRAMP Government Cloud platform. The solution is designed to strengthen compliance, improve consistency, streamline quality processes, and deliver greater insight across FDA's centers and offices. The initiative will focus on four priorities: Connected Quality Operations: Bringing document control, training, change, CAPA, audits, other key processes coupled with reporting to support consistent execution across the sites, functions, and organizational units. Trusted Data and Enterprise Visibility: Creating a centralized foundation for quality, risk and compliance data with end-to-end traceability and real-time insight across the agency. Intelligence and Automation: Applying AI and intelligent automation to accelerate investigations, surface relevant insights, identify emerging risks, and support better decisions. Secure, Scalable Federal Delivery: Combining a platform built to support large user populations, growing data volumes, and evolving regulatory requirements with Zolon PCS's federal expertise in cloud, cybersecurity, systems integration, and agile delivery. The FDA initiative reflects a broader shift across regulated environments. As operational complexity, regulatory expectations, and quality data volumes grow, organizations are moving beyond individual quality processes toward connected, enterprise-wide approaches. ComplianceQuest's QRC platform is built for this model, unifying Quality, Risk and Compliance across Product, Quality, Manufacturing, People, Suppliers, and Customers on a single, connected system. "Quality management is evolving from individual systems and processes toward connected enterprise platforms," said Prashanth Rajendran, CEO of ComplianceQuest. "We are proud to partner with Zolon PCS to support FDA's quality system modernization. This work highlights the growing need for technology that can meet the complexity, rigor, security, and evolving requirements of highly regulated environments." "We are honored by FDA's confidence in our team and proud to support its vital public health mission," said Goutham Amarneni, President of Zolon PCS. "Modernizing quality management at this scale takes both the right platform and the right delivery partner. Together with ComplianceQuest, we are bringing FDA a secure, AI-enabled solution built for the rigor of federal operations." About ComplianceQuest ComplianceQuest is the leading AI-powered Quality, Risk and Compliance (QRC) system that connects product, manufacturing, people, and partner quality in a single system. Built on Salesforce, the platform delivers end-to-end visibility, AI-driven intelligence, and enterprise-scale execution, enabling organizations to prevent risk, ensure compliance by design, and turn quality into a driver of growth. About Zolon PCS Zolon PCS, LLC is a joint venture between Pioneer Corporate Services and Zolon Tech, Inc., delivering advanced, secure, and mission-focused IT services and consulting to federal agencies. For more information, visit zolonpcs.zolontech.com. Media Contact ComplianceQuest: marketing@compliancequest.com | 408-458-8343 | www.compliancequest.com SOURCE: ComplianceQuest